NEW
Vyzulta

Vyzulta

latanoprostene bunod

Manufacturer:

Bausch & Lomb

Distributor:

DKSH

Marketer:

Bausch & Lomb
Concise Prescribing Info
Contents
Latanoprostene bunod
Indications/Uses
Reduction of IOP in patients w/ open-angle glaucoma or ocular HTN.
Dosage/Direction for Use
Adult including the elderly 1 drop in conjunctival sac of the affected eye(s) once daily in the evening.
Contraindications
Special Precautions
Not to be used more than once daily. New ocular condition (eg, trauma or infection), sudden decrease in visual acuity, have ocular surgery, or any ocular reactions, particularly conjunctivitis & eyelid reactions. Increased iris pigmentation & periorbital tissue (eyelid), including permanent changes. Possible eyelid skin darkening; eyelash & vellus hair changes in treated eye. Bacterial keratitis associated w/ use of multiple-dose containers of topical ophth products. History of intraocular inflammation (iritis/uveitis); known risk factors for macular edema. Aphakic & pseudophakic patients w/ torn posterior lens cap. Not to be used in patients w/ active intraocular inflammation. Remove contact lenses prior to, & reinsert 15 min after administration. Consider at least 5 min interval in concomitant use w/ other topical ophth products. May affect ability to drive or use machines. Pregnancy & lactation. Not recommended in ped ≤16 yr. Elderly.
Adverse Reactions
Eye pain & irritation, instillation site pain, conjunctival hyperemia.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EE06 - latanoprostene bunod ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Presentation/Packing
Form
Vyzulta ophth soln 0.24 mg/mL
Packing/Price
2.5 mL x 1's;5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in